To determine whether Syk is also required for FcγR-TLR cross-talk in M2 macrophages, we blocked Syk using R406 (also known as tamatinib), a kinase inhibitor that is currently also being tested for therapeutical use in RA patients33. This evidence concerns the gene FCGR2A and rheumatoid arthritis.